Dr Reddy’s Laboratories Ltd ADR

Yahoo Finance • 8 days ago

Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs

[Artificial Intelligence helping improve human life and health digital concept] Vertigo3d/E+ via Getty Images * Esperion Therapeutics (NASDAQ:ESPR [https://seekingalpha.com/symbol/ESPR]) announced it has reached a settlement with Dr. Re... Full story

Yahoo Finance • last month

Dr. Reddy's Laboratories (NYSE:RDY): A Peter Lynch-Style GARP Investment

For investors looking for a systematic method for long-term appreciation at fair prices, the investment philosophy of Peter Lynch offers a useful framework. Lynch, who notably achieved 29.2% average yearly returns while managing Fidelity’s... Full story

Yahoo Finance • last month

Factbox-Indian textiles, jewellery slapped with 50% Trump tariff; pharma, phones exempt

NEW DELHI (Reuters) -The United States has doubled tariffs on Indian imports to as much as 50% as scheduled on Wednesday, hitting goods and produce as varied as garments, jewellery and shrimp. Sectors such as smartphones, pharmaceuticals... Full story

Yahoo Finance • 2 months ago

Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading

Asian equities traded in the US as American depositary receipts were slightly higher on Thursday mor PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Dr. Reddy's Laboratories Breaks Above 200-Day Moving Average - Bullish for RDY

In trading on Monday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $14.25, changing hands as high as $14.47 per share. Dr. Reddy's Laboratories Ltd. shares are currently trading up ab... Full story

Yahoo Finance • 2 months ago

DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Fits Peter Lynch's Growth at a Reasonable Price (GARP) Strategy

Peter Lynch’s investment approach, detailed in _One Up on Wall Street_, centers on finding companies with steady growth at fair prices—commonly called the Growth at a Reasonable Price (GARP) method. This approach highlights key financial m... Full story

Yahoo Finance • 3 months ago

Dr. Reddy's stock price target raised to INR1,100 by Jefferies

Investing.com - Jefferies has raised the price target on Dr. Reddy’s Laboratories Ltd. (DRRD:IN) (NYSE:RDY) to INR1,100.00 from INR1,010.00 while maintaining an Underperform rating on the stock. The price target adjustment follows Dr. Red... Full story

Yahoo Finance • 3 months ago

Doctor Reddy's: Fiscal Q1 Earnings Snapshot

HYDERABAD, India (AP) — HYDERABAD, India (AP) — Dr. Reddy's Laboratories Ltd. (RDY) on Wednesday reported profit of $165 million in its fiscal first quarter. On a per-share basis, the Hyderabad, India-based company said it had net income... Full story

Yahoo Finance • 3 months ago

Dr. Reddy’s Laboratories (RDY) and Alvotech Enter Into a Collaboration and License Agreement

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years.Dr. Reddy’s Laboratories Limited (NYSE:RDY) and Alvotech announced that they have entered into a collaboration and license agreement to co... Full story

Yahoo Finance • 3 months ago

Dr. Reddy's Q1 Earnings Preview

* Dr. Reddy's (NYSE:RDY [https://seekingalpha.com/symbol/RDY]) is scheduled to announce Q1 earnings results on Wednesday, July 23rd, before market open. Over the last 1 year, RDY has beaten EPS estimates [https://seekingalpha.com/symbol... Full story

Yahoo Finance • 3 months ago

Dr. Reddy's Laboratories (RDY) Shares Cross Below 200 DMA

In trading on Tuesday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed below their 200 day moving average of $14.40, changing hands as low as $14.33 per share. Dr. Reddy's Laboratories Ltd. shares are currently trading off a... Full story

Yahoo Finance • 3 months ago

Morgan Stanley initiates coverage on Dr. Reddy's stock with Equalweight rating

Investing.com - Morgan Stanley initiated coverage on Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) with an Equalweight rating and a price target of INR1,298.00 on Monday. The research firm cited a balanced outlook for the Indian pharmaceutical... Full story

Yahoo Finance • 3 months ago

Macquarie downgrades Dr. Reddy's stock rating to Neutral on gRevlimid concerns

Investing.com - Macquarie downgraded Dr. Reddy’s Laboratories (DRRD:IN) (NYSE:RDY), a $12.46 billion pharmaceutical company with "GREAT" financial health according to InvestingPro analysis, from Outperform to Neutral and lowered its price... Full story

Yahoo Finance • 4 months ago

Global pharma stocks down as Trump renews tariff threat

Chip Somodevilla/Getty Images News Major global pharmaceutical companies traded lower in the premarket on Tuesday after President Donald Trump reiterated his plans to impose tariffs on pharmaceutical goods, a product category that has lar... Full story

Yahoo Finance • 4 months ago

Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Keytruda (pembrolizumab)

[Automated pharmaceutical production line. Robotic arms handling vials, ampoules in a modern cleanroom.] quantic69/iStock via Getty Images Alvotech (NASDAQ:ALVO [https://seekingalpha.com/symbol/ALVO]) and Dr. Reddy’s Laboratories (NYSE:RD... Full story

Yahoo Finance • 6 months ago

Dr. Reddy’s Laboratories (RDY): Among the Best Indian Stocks to Buy According to Billionaires

We recently published a list of the 10 Best Indian Stocks to Buy According to Billionaires. In this article, we will take a look at where Dr. Reddy’s Laboratories Limited (NYSE:RDY) stands against other best Indian stocks. India’s stock m... Full story

Yahoo Finance • 12 months ago

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

PRINCETON, N.J., October 14, 2024--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Inc., the U.S. arm of Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, today announced the launch of a comprehens... Full story

Yahoo Finance • last year

Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q4 2024 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q4 2024 Earnings Call Transcript May 7, 2024 Dr. Reddy's Laboratories Limited isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). O... Full story

Yahoo Finance • 3 years ago

Eton Pharmaceuticals Announces Sale of Hospital Products

Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 million Going forward, Eton’s commercial portfolio will exclusively focus on products that treat rare diseasesEton’s royalty... Full story

Yahoo Finance • 4 years ago

Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany

The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021. Dr. Reddy's will be the exclusive distributor of several of MediCane's medical cannabis products in Germany. Additionally, Dr. Red... Full story